Cardiovascular disease is the leading cause of death worldwide, accounting for 29% of all global deaths and is set to rise to 23 million deaths a year by 2030 (World Health Organisation, 2012). Arterial bypassing, both peripheral and coronary, is usually performed with autologously harvested vessels. However, the quantity available is often very limited as well as the vessels of elderly patients often suffering from thrombus, aneurysm formation or arthrosclerosis in high pressure arterial sites. The shortcomings of autografts has led to a substantial amount of research being directed towards tissue engineered vascular grafts (TEVGs) (Kakisis et al., 2005). Currently available artificial grafts for small diameter vasculature (mm) suffer from...
Due to the limited success rate of currently available vascular replacements, tissue engineering has...
Due to the limited success rate of currently available vascular replacements, tissue engineering has...
Current synthetic alternatives to autologous grafts have often failed in small diameter applications...
Cardiovascular disease is the leading cause of death worldwide, accounting for 29% of all global dea...
Cardiovascular diseases are the leading cause of death worldwide. Blood vessel replacement is a comm...
BackgroundArterial bypass graft implantation remains the primary therapy for patients with advanced ...
Clinically available heart valve replacements consist of non-living materials, lacking the ability t...
Cardiovascular disease is the leading cause of death worldwide, with this trend predicted to continu...
Compliance mismatch is a significant hurdle to long-term patency in small-diameter arterial bypass g...
Clinically available heart valve replacements consist of non-living materials, lacking the ability t...
For small diameter (<6 mm) blood vessel replacements, lack of collaterals and vascular disease precl...
Compliance mismatch is a significant hurdle to long-term patency in small-diameter arterial bypass g...
Due to the limited success rate of currently available vascular replacements, tissue engineering has...
Compliance mismatch is a significant challenge to long-term patency in small-diameter bypass grafts ...
ObjectiveVarious tissue-engineered vascular grafts have been studied to overcome the clinical disadv...
Due to the limited success rate of currently available vascular replacements, tissue engineering has...
Due to the limited success rate of currently available vascular replacements, tissue engineering has...
Current synthetic alternatives to autologous grafts have often failed in small diameter applications...
Cardiovascular disease is the leading cause of death worldwide, accounting for 29% of all global dea...
Cardiovascular diseases are the leading cause of death worldwide. Blood vessel replacement is a comm...
BackgroundArterial bypass graft implantation remains the primary therapy for patients with advanced ...
Clinically available heart valve replacements consist of non-living materials, lacking the ability t...
Cardiovascular disease is the leading cause of death worldwide, with this trend predicted to continu...
Compliance mismatch is a significant hurdle to long-term patency in small-diameter arterial bypass g...
Clinically available heart valve replacements consist of non-living materials, lacking the ability t...
For small diameter (<6 mm) blood vessel replacements, lack of collaterals and vascular disease precl...
Compliance mismatch is a significant hurdle to long-term patency in small-diameter arterial bypass g...
Due to the limited success rate of currently available vascular replacements, tissue engineering has...
Compliance mismatch is a significant challenge to long-term patency in small-diameter bypass grafts ...
ObjectiveVarious tissue-engineered vascular grafts have been studied to overcome the clinical disadv...
Due to the limited success rate of currently available vascular replacements, tissue engineering has...
Due to the limited success rate of currently available vascular replacements, tissue engineering has...
Current synthetic alternatives to autologous grafts have often failed in small diameter applications...